RUNX1 and acute myeloid leukemia: Consistent with their discovery, HNT-34, EVI1-driven AML cells were highly sensitive to HDAC3 inhibition (0.1 micromolar RGFP966 was sufficient to significantly decrease cell growth) as compared to EVI1/ERG-independent MLL (KMT2A)- rearranged AML cells (Fig. 9B).